A2780cis Cell Line
- Name Timothy Ward
- Institute National Institutes of Health
Tool name: A2780cis Cell Line
Tool type: Cell Lines
Tool sub-type: Continuous
Parental cell line: A2780
Cancer type: Human ovarian carcinoma
Description: A2780 cell line resistant to cisplatin.
Background and Research Application
The cisplatin-resistant A2780cis cell line has been developed by chronic exposure of the parent cisplatin-sensitive A2780 cell line (catalogue no. 152706) to increasing concentrations of cisplatin. This cell line was derived from a patient with ovarian endometroid adenocarcinoma. A2780cis is cross-resistant to melphalan, adriamycin and irradiation. An increased ability to repair DNA damage as well as cytogenetic abnormalities has been observed. In order to retain resistance cisplatin has to be added to the media for every passage. In addition to this matched pair of drug-sensitive/resistant cell lines an adriamycin-resistant cell line, A2780adr (catalogue no. 152707), has been isolated from the same parental line.
A2780cis has been used in a variety of experiments, including studying the cytotoxic effects of platinum (II) complexes and gold (I)-triphenylphosphine complexes with hypoxanthine-derived ligands. It has also been used to study the effects of cancer-cell specific oligopeptides.
Research area: Cancer ; Drug Discovery & Development
- For Research Use Only
- • Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
- • Beaufort et al. 2014. PLoS One. 9(9):e103988. PMID: 25230021.
- • Marcotte et al. 2012. Cancer Discov. 2(2):172-189. PMID: 22585861.
- • Rothenberg et al. 2010. Cancer Res. 70(6):2158-64. PMID: 20215515.
- • Masuda et al. 1988. Cancer Res. 48(20):5713-6. PMID: 3139281.
- • Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.
- • Behrens et al. 1987. Cancer Res. 47(2):414-8. PMID: 3539322.
- • Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.